期刊论文详细信息
Journal of Nuclear Medicine
Tumor Imaging in Patients with Advanced Tumors Using a New 99mTc-Radiolabeled Vitamin B12 Derivative
Niklaus G. Schaefer1  Robert Waibel1  Ebba Nexo1  Jan D. Soyka1  Peter Bläuenstein1  Eliane Fischer1  Anass Johayem1  Ennio Müller1  Bert-Ram Sah1  Stefan K. Haerle1  Pius August Schubiger1  Lotta von Boehmer1  Alexander K. Knuth1  Irene A. Burger1  Roger Schibli1 
关键词: vitamin B12;    cancer;    transcobalamin receptors;    haptocorrin;    cobalamin;   
DOI  :  10.2967/jnumed.113.122499
学科分类:医学(综合)
来源: Society of Nuclear Medicine
PDF
【 摘 要 】

Targeting cancer cells with vitamin B12 (cobalamin) is hampered by unwanted physiologic tissue uptake mediated by transcobalamin. Adhering to good manufacturing practice, we have developed a new 99mTc-cobalamin derivative (99mTc(CO)3-[(4-amido-butyl)-pyridin-2-yl-methyl-amino-acetato] cobalamin, 99mTc-PAMA-cobalamin). The derivative shows no binding to transcobalamin but is recognized by haptocorrin, a protein present in the circulation and notably expressed in many tumor cells. In this prospective study, we investigated cancer-specific uptake of 99mTc-PAMA-cobalamin in 10 patients with various metastatic tumors. Methods: Ten patients with biopsy-proven metastatic cancer were included. Dynamic imaging was started immediately after injection of 300–500 MBq of 99mTc-PAMA-cobalamin, and whole-body scintigrams were obtained at 10, 30, 60, 120, and 240 min and after 24 h. The relative tumor activity using SPECT/CT over the tumor region after 4 h was measured in comparison to disease-free lung parenchyma. Patients 3–10 received between 20 and 1,000 μg of cobalamin intravenously before injection of 99mTc-PAMA-cobalamin. The study population comprised 4 patients with adenocarcinomas of the lung, 3 with squamous cell carcinomas of the hypopharyngeal region, 1 with prostate adenocarcinoma, 1 with breast, and 1 with colon adenocarcinoma. Results: The median age of the study group was 61 ± 11 y. Six of 10 patients showed positive tumor uptake on 99mTc-PAMA-cobalamin whole-body scintigraphy. The scan was positive in 1 patient with colon adenocarcinoma, in 3 of 4 lung adenocarcinomas, in 1 of 3 hypopharyngeal squamous cell carcinomas, and in 1 breast adenocarcinoma. Renal uptake was between 1% and 3% for the left kidney. Predosing with cobalamin increased the tumor uptake and improved blood-pool clearance. The best image quality was achieved with a predose of 20–100 ug of cold cobalamin. The mean patient dose was 2.7 ± 0.9 mSv/patient. Conclusion: To our knowledge, we report for the first time on 99mTc-PAMA-cobalamin imaging in patients with metastatic cancer disease and show that tumor targeting is feasible.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201912010198932ZK.pdf 1014KB PDF download
  文献评价指标  
  下载次数:12次 浏览次数:8次